Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in...
HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody...
Tampa General’s Innovation Week Returns with New Programming to Showcase Breakthroughs...
Global leaders, entrepreneurs and innovators will converge across the Tampa Medical & Research District and TGH locations region-wide to showcase breakthrough technologies, bold ideas...
FDA Breakthrough Therapy Designation Granted for Litifilimab for Cutaneous Lupus
Results from the phase 2 LILAC study are key in gaining this FDA designation.
Source link
FDA Grants Breakthrough Designation to Zovegalisib for Breast Cancer
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to zovegalisib in combination with Faslodex (fulvestrant) for some patients with...
Treatment Advances Position Lilly as Weight-Loss Heavyweight
For every patient Eli Lilly helped downsize with its obesity drug Zepbound, rival Novo Nordisk’s purse got a little lighter, too.
After Novo reported disappointing...
World Cancer Day 2026: Significance, Theme And 7 Breakthroughs In Cancer...
Each year, February 4 is commemorated as World Cancer Day to raise awareness among the population about cancer, encourage prompt detection and prevention, and support global initiatives...
Highlighting Advances in Chondrosarcoma and TGCT Treatment | Targeted Oncology
At the 4th Annual Miami Cancer Institute Precision Oncology Symposium on January 30 to 31, 2026, Neeta Somaiah, MD, professor and department chair...
Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus
Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus (CLE).
CLE is a chronic autoimmune skin disorder characterised...